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Background
Soluble guanylate cyclase (sGC), the key transducer of
nitric oxide (NO) signaling, exists in two redox forms: the
NO sensitive ferrous heme iron (Fe(II)) form and a NO
insensitive oxidized form containing the ferric heme iron
(Fe(III)). Ataciguat sodium (further named ataciguat) pre-
dominantly stimulates the oxidized form of sGC. To fur-
ther define the therapeutic potential of ataciguat in
cardiovascular disease, we investigated its effect in various
in vivo models of: platelet aggregation, atherosclerosis
and peripheral arterial occlusive disease.
Platelet activation
Thrombus formation in a coronary artery is the acute
event in most unstable ischemic coronary syndromes.
Ataciguat, which induced no hemodynamic effects, signif-
icantly reduced the number of cycles (the readout of
thrombus formation) in a canine model of coronary
thrombosis (Folts model). In contrast to aspirin, the effect
of ataciguat was not abolished by epinephrine, suggesting
that ataciguat will be effective under conditions of
increased sympathetic tone.
Diabetes mellitus is associated with an increased throm-
boembolic risk via activation of circulating platelets as
well as the development of endothelial and vascular dys-
function. Both effects have been attributed to a lack of
nitric oxide (NO) bioavailability and/or reduced sensitiv-
ity of sGC for NO. A single intravenous injection of strep-
tozotocine (STZ) to rats induced type I diabetes and
attenuated NO-stimulated sGC activity isolated from
aorta as compared to the placebo injected control group,
while the ataciguat stimulated sGC activity was not differ-
ent between both groups. Chronic treatment of STZ dia-
betic rats with ataciguat normalized platelet activation as
measured by a reduction of P-selectin expression and an
increase in platelet vasodilator stimulated phosphopro-
tein (VASP) phosphorylation. Activation of sGC by ataci-
guat normalized vascular function and restored
endothelium dependent relaxation in isolated aortic rings
from control and placebo treated STZ rats.
Atherosclerosis and endothelial function
An impairment of NO signaling has been shown to be
involved in the development of endothelial dysfunction
and atherosclerosis. We therefore investigated the effects
of ataciguat in a mouse model of atherosclerosis. Apolipo-
protein E-deficient (ApoE-/-) mice were fed a high-fat
high-cholesterol diet, or the respective diets supple-
mented with ataciguat. At the end of the treatment peri-
ods, there were no significant differences in plasma
cholesterol concentrations or blood pressure between the
groups. Compared to wild-type mice, placebo-treated
ApoE-/- mice developed profound endothelial dysfunc-
tion, as indicated by an impaired endothelium-dependent
vasodilatation, and severe atherosclerotic lesion forma-
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tion in the aortic root and the ascending aorta. In contrast,
ataciguat treatment significantly reduced atherosclerotic
plaque formation and markedly improved endothelium-
dependent vasodilatation. Treatment with ataciguat had
no effect on endothelium-independent vasorelaxation or
vasoconstriction. Aortic release of reactive oxygen species
was increased in ApoE-/- mice as compared to wild-type
mice, but was not affected by treatment. Ataciguat led to
increased expression of vascular P-VASP, a downstream
target of sGC, did not alter eNOS and sGC expression, and
reduced vascular VCAM-1 expression.
Peripheral arterial occlusive disease
The main characteristic of stage II peripheral arterial
occlusive disease is exercise-induced muscle fatigue. The
effect of placebo, ataciguat, cilostazol, and a combination
of both treatments was studied in Zucker Diabetic Fatty
(ZDF) rats with unilateral hind limb ischemia.
Placebo-treated animals showed marked signs of exercise-
induced muscle fatigue, with a mildly reduced contraction
force, moderately reduced contraction velocity, severely
reduced relaxation velocity, and markedly prolonged time
to recovery after 10 min of continuous contractions (80/
min). All of these parameters significantly improved to a
similar extent in animals treated with either ataciguat, or
cilostazol alone. The combination of both treatments
showed an even more pronounced reduction of muscle
fatigue.
Conclusion
The sGC activator ataciguat inhibits platelet activation in
an acute model of coronary thrombosis, normalizes plate-
let activation and restores endothelial and vascular func-
tion in type-I diabetic rats, improves endothelial function
and reduces atherosclerosis in ApoE deficient mice, and
improves ischemia-induced muscle fatigue in a rat model
of peripheral arterial occlusive disease. Based on these
data the ACCELA Trial, a 6 months randomized, double-
blind, placebo-controlled dose-ranging trial of ataciguat
for patients with intermittent claudication, has been initi-
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